Table 3.
Univariate and Multivariate Analysis for Local Recurrence-free and Metastasis-free Survival in Patients with Undifferentiated Pleomorphic Sarcoma
| Local recurrence-free survival | Metastasis-free survival | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Covariate, (indicator ) | Univariable | Multivariable (n = 145)† | Univariable | Multivariable (n = 175)† | |||||
|
| |||||||||
| HR (95%CI) | P-value | HR (95%CI) | P-value | HR (95%CI) | P-value | HR (95%CI) | P-value | ||
| Clinical markers | Age, (<61) v. ≥61 | 0.78 (0.46–1.34) | 0.372 | 0.59 (0.35–1.00) | 0.051** | 0.53 (0.28–1.00) | 0.052 | ||
| Setting, sporadic v. RAS | 0.38 (0.21–0.69) | 0.002* | 0.29 (0.15–0.56) | <0.001 | 0.75 (0.40–1.41) | 0.378 | |||
| Size, <10 cm v. ≥10 cm | 0.68 (0.39–1.2) | 0.149 | 0.41 (0.25–0.68) | 0.001* | 0.36 (0.19–0.66) | 0.001 | |||
| Depth, superficial v. deep | 0.81 (0.37–1.79) | 0.600 | 0.61 (0.26–1.42) | 0.250 | |||||
| Grade, low-intermediate v. high | 0.91 (0.22–3.77) | 0.898 | 0.31 (0.04–2.24) | 0.245 | |||||
| Chemotherapy, no v. yes | 0.87 (0.49–1.52) | 0.619 | 1.18 (0.67–2.05) | 0.569 | |||||
| Radiation, no v. yes | 0.78 (0.46–1.35) | 0.782 | 1.23 (0.75–2.02) | 0.409 | |||||
| Margins, negative v. positive | 0.51 (0.29–0.87) | 0.013* | 0.45 (0.24–0.87) | 0.018 | 0.71 (0.42–1.18) | 0.187 | |||
|
| |||||||||
| Protein markers | Ki67, negative v. positive | 1.25 (0.67–2.35) | 0.480 | 0.88 (0.49–1.55) | 0.653 | ||||
| Cyclin D1, negative v. positive | 0.97 (0.53–1.79) | 0.928 | 1.19 (0.67–2.11) | 0.549 | |||||
| CD31, negative-low v. high | 1.19 (0.37–3.87) | 0.773 | 0.62 (0.24–1.58) | 0.317 | |||||
| p53, negative v. positive | 0.86 (0.48–1.56) | 0.624 | 1.02 (0.58–1.81) | 0.936 | |||||
| AXL Receptor, negative v. positive | 0.71 (0.37–1.37) | 0.309 | 0.58 (0.31–1.11) | 0.100 | |||||
| c-kit, negative v. positive | 1.17 (0.46–2.98) | 0.741 | 1.12 (0.45–2.84) | 0.803 | |||||
| pEGFR, negative v. positive | 0.63 (0.32–1.20) | 0.161 | 1.23 (0.64–2.39) | 0.534 | |||||
| pIGF1R, negative-low v. high | 0.60 (0.32–1.15) | 0.126 | 0.86 (0.43–1.71) | 0.660 | |||||
| IGF1R, negative v. positive | 0.57 (0.30 1.09) | 0.092** | 0.72 (0.37–1.39) | 0.329 | 0.80 (0.43–1.49) | 0.482 | |||
| pMET, negative-low v. high | 1.66 (0.39–7.12) | 0.492 | 3.00 (0.39–22.8) | 0.287 | |||||
| PTEN, negative v retained | 6.25 (2.18–17.9) | 0.001* | 5.29 (1.77–15.9) | 0.003 | 8.68 (3.33–22.7) | <0.001* | 7.98 (2.89–22.0) | <0.001 | |
| pAKT (Cytoplasmic), negative-low v. high | 0.89 (0.48–1.68) | 0.732 | 0.64 (0.36–1.11) | 0.636 | |||||
| pAKT (Nuclear), negative-low v. high | 0.85 (0.46–1.56) | 0.603 | 0.96 (0.55–1.67) | 0.878 | |||||
| AKT (Cytoplasmic), negative-low v. high | 1.56 (0.80–3.04) | 0.192 | 1.00 (0.56–1.81) | 0.982 | |||||
| AKT (Nuclear), negative-low v. high | 0.91 (0.48–1.70) | 0.909 | 0.76 (0.43–1.36) | 0.357 | |||||
| pS6RP, negative v positive | 1.54 (0.80–2.95) | 0.193 | 1.24 (0.69–2.26) | 0.472 | |||||
| S6RP, negative-low v. high | 0.77 (0.37–1.60) | 0.479 | 0.83 (0.42–1.62) | 0.577 | |||||
| P4EBP1 (Cytoplasmic), negative v positive | 0.92 (0.51–1.69) | 0.798 | 1.04 (0.59–1.82) | 0.883 | |||||
|
| |||||||||
| miRNA markers | miR-1, negative-low v. high | 1.87 (0.83–4.21) | 0.132 | 0.79 (0.36–1.75) | 0.572 | ||||
| miR-133a, negative-low v. high | 0.75 (0.33–1.66) | 0.472 | 1.12 (0.46–2.69) | 0.804 | |||||
| miR-183, negative-low v. high | 1.14 (0.52–2.49) | 0.740 | 0.65 (0.31–1.35) | 0.246 | |||||
| miR-182, negative-low v. high | 1.00 (0.34–2.95) | 0.992 | 2.36 (0.56–9.93) | 0.242 | |||||
*
Significant at level of p < 0.05
**
Significant at level of p <0.1
†
Patients without expression scores for all molecular variables included in the multivariate analysis are excluded